转移性去势抵抗性前列腺癌患者接受[177Lu]Lu-PSMA-617放射配体治疗中的病灶吸收剂量-反应关系
65例转移性去势抵抗性前列腺癌患者接受[177Lu]Lu-PSMA-617放射配体治疗,行SPECT/CT系列显像及单时间点与多时间点体素剂量学。病灶平均吸收剂量与患者及病灶反应呈中度负相关;平均吸收剂量>7.5 Gy者前列腺特异性抗原反应及生化无进展生存更优。单时间点剂量学可行,有利于治疗个体化实施。
要点
- 基线PET与SPECT病灶SUVmax强相关(Pearson r=0.74;n=1364个病灶)。
- 患者平均病灶吸收剂量与反应呈中度负相关(Spearman ρ=-0.33;n=63)。
- 平均吸收剂量>7.5 Gy者PSA反应更优(中位70% vs -5%;P<0.001)且生化无进展生存更长(中位4.1个月 vs 1.6个月;P=0.005)。
核心结论
- 在转移性去势抵抗性前列腺癌患者接受[177Lu]Lu-PSMA-617放射配体治疗中观察到中度吸收剂量-反应关系。
- 单时间点剂量学的可行性有利于其用于治疗个体化实施。
- 充分水化可能降低肾脏吸收剂量。
研究设计与样本
- 65例患者接受7.31±0.27 GBq的[177Lu]Lu-PSMA-617后行系列SPECT/CT显像。
- 采用单时间点剂量学(72小时Hänscheid近似)与多时间点体素剂量学。
- 患者反应通过第1周期放射配体治疗前后血清前列腺特异性抗原水平变化评估。
- 单个病灶反应通过[68Ga]Ga-PSMA-11 PET/CT在放射配体治疗前、中、后SUVmax变化评估。
主要发现
- 基线PET与SPECT病灶SUVmax强相关(Pearson r=0.74;n=1364个病灶)。
- 肾脏吸收剂量相对较低(0.28±0.12 Gy/GBq),放射配体治疗后1年估算肾小球滤过率未见显著下降。
- 单时间点剂量学平均低估吸收剂量8%。
- 患者平均病灶吸收剂量与患者反应呈中度负相关(Spearman ρ=-0.33;n=63),与病灶反应亦呈中度负相关(Spearman ρ=-0.30;n=681)。
- 平均吸收剂量>7.5 Gy者较<7.5 Gy者前列腺特异性抗原反应更优(中位70% vs -5%;P<0.001;非配对t检验),生化无进展生存更长(中位4.1个月 vs 1.6个月;P=0.005;非配对t检验)。
关键数值与推荐
- 平均病灶吸收剂量阈值7.5 Gy:>7.5 Gy者前列腺特异性抗原反应中位70%,<7.5 Gy者为-5%(P<0.001)。
- 平均病灶吸收剂量阈值7.5 Gy:>7.5 Gy者生化无进展生存中位4.1个月,<7.5 Gy者为1.6个月(P=0.005)。
- 肾脏吸收剂量0.28±0.12 Gy/GBq。
- 单时间点剂量学较多时间点体素剂量学平均低估吸收剂量8%。
临床怎么用
- 作者认为单时间点剂量学的可行性有利于其用于治疗个体化实施。
- 作者提出充分水化可能降低肾脏吸收剂量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The relationship between lesion absorbed dose (AD) and response in patients with metastatic castration-resistant prostate cancer undergoing [177Lu]Lu-PSMA-617 radiopharmaceutical therapy (RPT) remains poorly understood. The objective of this work was to investigate the AD-response relationship at both the patient and lesion levels. Methods: Sixty-five patients underwent serial SPECT/CT imaging after receiving 7.31 ± 0.27 GBq of [177Lu]Lu-PSMA-617. Single-time-point (STP) (Hänscheid approximation at 72 h) and multiple-time-point voxelwise dosimetry were performed. Patient response was evaluated by changes in serum prostate-specific antigen level before and after cycle 1 of RPT. The response of individual lesions was evaluated by the change in the SUVmax before, during, and after RPT with [68Ga]Ga-PSMA-11 PET/CT. Results: Baseline PET and SPECT lesion SUVmax were strongly correlated (Pearson r, 0.74; n = 1364 lesions). Kidney ADs were relatively low (0.28 ± 0.12 Gy/GBq). No significant decrease in estimated glomerular filtration rate was observed 1 y after RPT. On average, STP dosimetry underestimated the AD by 8%. A moderate negative relationship was observed between the mean lesion AD for an individual patient (Spearman ρ, -0.33; n = 63) and lesion (Spearman ρ, -0.30; n = 681) responses. Patients receiving a higher mean AD (>7.5 Gy) had a significantly better prostate-specific antigen response (median, 70% vs. -5%; P < 0.001; unpaired t test) and longer biochemical progression-free survival (median, 4.1 mo vs. 1.6 mo; P = 0.005; unpaired t test) compared with patients whose mean AD was less than 7.5 Gy, respectively. Conclusion: A moderate AD-response relationship was observed in patients with metastatic castration-resistant prostate cancer undergoing [177Lu]Lu-PSMA-617 RPT. The feasibility of STP dosimetry facilitates its implementation for treatment personalization. Kidney ADs may be reduced with abundant hydration.
引用
- Grkovski M, Krebs SS, O'Donoghue JA, et al. Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy. J Nucl Med. 2025. PMID: 40774698. doi:10.2967/jnumed.125.270170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。